bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
PATHADD09

Order Name:
MMR (Mismatch Repair), IHC: MLH1, MSH2, MSH6, PMS2

 
Useful For:
Evaluation of tumor tissue to identify patients at risk for having hereditary nonpolyposis colon cancer/Lynch syndrome
 
Methodology:
Immunohistochemistry
 
Test List In Profile:
MLH1, MSH2, MSH6, PMS2
 
AliasesName:
Mismatch Repair Proteins
 
 
 
Test Code:
PATHADD09

Order Name:
MMR (Mismatch Repair), IHC: MLH1, MSH2, MSH6, PMS2

 
Collection Specimen Or Container:
1. Tissue in 10% neutral buffered formalin or 
2. Paraffin embedded tissue block or
3. Unstained positively charged slides as least 4 slides
 
Specimen Testing Type:
1. Tissue in 10% neutral buffered formalin or 
2. Paraffin embedded tissue block or
3. Unstained positively charged slides as least 4 slides
 
Sub Mission Container:
1. Tissue in 10% neutral buffered formalin or 
2. Paraffin embedded tissue block or
3. Unstained positively charged slides as least 4 slides
 
Rejection Criteria:
1. Specimens that have been decalcified (all methods)
2. Specimens that have not been formalin-fixed
3. Paraffin-embedded; bone marrow in EDTA
 
Specimen Stabillity:
 
Specimen Type Temperature
Tissue 1. Room temperature for Tissue in 10% neutral buffered formalin
2. Room temperature for paraffin embedded tissue block and unstained slide
 
 
 
Test Code:
PATHADD09

Order Name:
MMR (Mismatch Repair), IHC: MLH1, MSH2, MSH6, PMS2

 
Method detail:
Immunohistochemistry
 
Schedule:
Tested daily, at 07:00 am. - 06:00 pm.
 
Turnaround Time:
5-7 days
 
Performing Location:
Surgical Pathology, Laboratory Department Tel.14146
 
Specimen Retention Time:
10 years after final report
 
 
 
Test Code:
PATHADD09

Order Name:
MMR (Mismatch Repair), IHC: MLH1, MSH2, MSH6, PMS2

 
 
Clinical Information:
A well-defined subtype of colorectal cancer (CRC) is characterized by deficiencies in the mismatch repair (MMR) pathway. MMR status may impact prognosis and benefit of adjuvant chemotherapy. MLH1, MSH2, MSH6, and PMS2 protein expression (as assessed by IHC) and microsatellite instability analysis (MSI) assessed by PCR are well-established tools to screen for Lynch syndrome (LS), and such testing is recommended for all new colorectal cancer diagnoses. MMR IHC and molecular MSI testing also serve as companion diagnostic tests in a wide range of solid tumors for selection of certain immuno-oncology therapies.
 
Clinical Reference:
1. https://www.mayocliniclabs.com (Retrieved: 1 Feb 2019) 2. https://neogenomics.com/test-menu/mmr-panel-ihc-mlh1-msh2-msh6-pms2 (Retrieved: 29 Jan 2019)